High-avidity T cells are preferentially tolerized in the tumor microenvironment
about
Identifying Individual T Cell Receptors of Optimal Avidity for Tumor AntigensTo affinity and beyond: harnessing the T cell receptor for cancer immunotherapyElimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.T cell avidity and tumor immunity: problems and solutionsTransforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expressionGenetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity.Changes of plasma cytokines and chemokines expression level in nasopharyngeal carcinoma patients after treatment with definitive intensity-modulated radiotherapy (IMRT).FOXO3-NF-κB RelA Protein Complexes Reduce Proinflammatory Cell Signaling and FunctionImmune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers.Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized miceChimeric Antigen Receptor (CAR) therapy for multiple myeloma.T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade.SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.Spontaneous presence of FOXO3-specific T cells in cancer patients.Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms.Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells.The inhibition effect of starch nanoparticles on tyrosinase activity and its mechanism.Frequent adaptive immune responses against arginase-1.Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial.
P2860
Q26774669-3E2CC96E-2A77-44D6-9366-F398FD6D1302Q27008423-286BDA1B-40CB-44AE-941D-B8AC048C50B1Q33679779-4181CCAF-BB5B-4E61-9A8E-429454FF9B82Q34115960-4879E719-3601-469F-92DD-580635A85C98Q34240499-E7C8E6C7-CF0C-41C1-A74D-818C1D51D8E9Q35691240-424BF7E1-9D0F-4C89-9631-ADFC756AEC87Q36282747-ECBAB93D-3522-4F3A-9A6B-11A4E577B11FQ36349658-11DA82AD-1EAA-4E07-888E-323FA1411DCFQ36813010-BBFEA7EC-B9C3-4503-AD0F-97F19FF0EAEEQ37622152-F4E1927E-985A-43A7-9D1E-D20938B104B7Q37725761-8E89D5E5-864B-4902-905F-0C879587BC29Q38704573-D9B42219-6C36-4C37-A15F-6C4FF3F356C5Q38746598-75C5836D-E7A5-4DF4-B2A4-BDC3450C7E97Q39043196-1E5AED08-91C3-43B8-BEA5-70F0242AA5FDQ40188258-72FF61A0-D39D-4123-8E48-554A449FED7FQ41894814-ECCCBD61-F927-4E9D-BE08-061C31BD9FA8Q41939949-06C8602E-9BC7-47C2-9D6F-35B686412900Q43196241-B0FDEFBA-B27A-4B18-8728-B2A9CE582F84Q47113506-053EC878-5C71-46D0-8DF6-9414548E34AFQ50222492-453A5207-796E-45DA-A4AE-490B48A2360AQ51052882-66807B49-BA73-4508-8A2B-D4B4B5D86EA8Q52733766-89A8E676-C7DE-4363-817B-BF303E669CE4Q55235076-5B30AB31-AFC6-4F6C-B63A-DB2A109F48E4
P2860
High-avidity T cells are preferentially tolerized in the tumor microenvironment
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
High-avidity T cells are preferentially tolerized in the tumor microenvironment
@ast
High-avidity T cells are preferentially tolerized in the tumor microenvironment
@en
High-avidity T cells are preferentially tolerized in the tumor microenvironment
@nl
type
label
High-avidity T cells are preferentially tolerized in the tumor microenvironment
@ast
High-avidity T cells are preferentially tolerized in the tumor microenvironment
@en
High-avidity T cells are preferentially tolerized in the tumor microenvironment
@nl
prefLabel
High-avidity T cells are preferentially tolerized in the tumor microenvironment
@ast
High-avidity T cells are preferentially tolerized in the tumor microenvironment
@en
High-avidity T cells are preferentially tolerized in the tumor microenvironment
@nl
P2093
P2860
P1433
P1476
High-avidity T cells are preferentially tolerized in the tumor microenvironment
@en
P2093
Arthur A Hurwitz
Jennifer L Shoe
Lionel Feigenbaum
Stephanie K Watkins
Vincenzo Bronte
Vinod Singh
Ziqiang Zhu
P2860
P304
P356
10.1158/0008-5472.CAN-12-1123
P407
P577
2012-11-30T00:00:00Z